CN113750146A - External application traditional Chinese medicine formula for treating cardiac hypertrophy - Google Patents

External application traditional Chinese medicine formula for treating cardiac hypertrophy Download PDF

Info

Publication number
CN113750146A
CN113750146A CN202111025365.6A CN202111025365A CN113750146A CN 113750146 A CN113750146 A CN 113750146A CN 202111025365 A CN202111025365 A CN 202111025365A CN 113750146 A CN113750146 A CN 113750146A
Authority
CN
China
Prior art keywords
parts
chinese medicine
traditional chinese
external application
gauze
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111025365.6A
Other languages
Chinese (zh)
Inventor
吴绍伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111025365.6A priority Critical patent/CN113750146A/en
Publication of CN113750146A publication Critical patent/CN113750146A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses an external application traditional Chinese medicine formula for treating cardiac hypertrophy, wherein the basic formula comprises astragalus, peach kernel, safflower, salvia miltiorrhiza, earthworm, cocklebur fruit, bufonis and nepenthes.

Description

External application traditional Chinese medicine formula for treating cardiac hypertrophy
Technical Field
The invention relates to the technical field of medicines, in particular to an external application traditional Chinese medicine formula for treating myocardial hypertrophy.
Background
Myocardial hypertrophy is a compensatory function which generates slower but more effective action, mainly occurs in the condition of long-term pressure overload, the total amount of the myocardium is increased, the contractility is strengthened, and the heart can maintain normal blood circulation and has considerable reserve capacity. However, this compensatory function is also disadvantageous, mainly because the hypertrophied myocardium has increased oxygen demand, and the blood supply to the coronary arteries is often not satisfied, resulting in myocardial ischemia, which ultimately leads to a decrease in myocardial contractility. Myocardial hypertrophy is an independent risk factor for cardiovascular accidents, and is more harmful than smoking, hypercholesterolemia and the like. Researches show that the incidence rate of cardiovascular events such as sudden death, ventricular arrhythmia, myocardial ischemia, heart failure and the like is increased by 6-10 times along with the occurrence and development of left ventricular hypertrophy. Therefore, the positive treatment of myocardial hypertrophy inevitably reduces the occurrence of cardiovascular events to satisfy the desire of human beings for longevity. Myocardial hypertrophy is a common pathological process of a plurality of cardiovascular diseases such as cardiomyopathy, hypertension, myocardial infarction, valvulopathy and the like, is adaptive compensation reaction to various cardiovascular stimulating factors such as hemodynamic load, angiotensin, growth factors, hormones and the like, and can reduce wall tension and maintain or even increase cardiac output. However, persistent pathological myocardial hypertrophy from chronic stress can progress to cardiac enlargement, congestive heart failure and sudden death. Therefore, myocardial hypertrophy is considered to be an independent risk factor and a poor prognostic signature for cardiovascular disease.
At present, although the types of medicines for treating the left ventricular myocardial hypertrophy are various, the single-target treatment effect of western medicines does not reach an ideal state. The traditional Chinese medicine has the treatment advantages of rich bioactive components and multiple target spots, and has a very bright prospect for treating myocardial hypertrophy.
Disclosure of Invention
Therefore, based on the background, the invention aims to provide an external application traditional Chinese medicine formula for treating cardiac hypertrophy, which can avoid the problem of gastrointestinal discomfort caused by oral administration through external application, has no side effect and has a remarkable effect.
The technical scheme provided by the invention is as follows:
an external application traditional Chinese medicine prescription for treating cardiac hypertrophy comprises the following raw material medicines: astragalus root, peach kernel, safflower, root of red rooted saliva, earthworm, siberian cocklour fruit, toad venom and nepenthes.
Further, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight:
20-50 parts of astragalus membranaceus, 20-50 parts of peach kernels, 20-50 parts of safflower, 20-50 parts of salvia miltiorrhiza, 20-50 parts of lumbricus, 20-50 parts of cocklebur fruits, 20-50 parts of bufonid, 20-50 parts of pig-leaf weeds, 20-50 parts of radix bupleuri, 20-50 parts of fructus aurantii and 20-50 parts of fructus toosendan.
Further, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
20-50 parts of astragalus membranaceus, 20-50 parts of peach kernels, 20-50 parts of safflower, 20-50 parts of salvia miltiorrhiza, 20-50 parts of lumbricus, 20-50 parts of cocklebur fruits, 20-50 parts of bufonid, 20-50 parts of pig-leaf weeds, 20-50 parts of poria cocos, 20-50 parts of bighead atractylodes rhizome and 20-50 parts of monkshood.
Further, the using method comprises the following steps: weighing the raw materials according to the amount, adding water to prepare decoction, soaking the decoction into a plurality of layers of gauze, taking out the plurality of layers of gauze until no liquid medicine drips, placing the gauze on an affected part of a heart for external application, and controlling the medicine on the gauze to be about 42 ℃ in the external application process.
The basic formula of the invention comprises the following medicaments: astragalus root, peach kernel, safflower, root of red rooted saliva, earthworm, siberian cocklour fruit, toad venom and pig's leafflower herb, wherein the astragalus root has the functions of invigorating qi, consolidating superficial resistance, promoting urination, expelling toxin and the like, and the peach kernel has the functions of activating blood circulation, removing stasis and the like; the safflower has the efficacies of promoting blood circulation, stimulating the menstrual flow, dissipating blood stasis, relieving pain and the like; the salvia miltiorrhiza has the effects of removing blood stasis, relieving pain, promoting blood circulation, stimulating the menstrual flow and the like; the earthworm has the effects of clearing heat, arresting convulsion, dredging collaterals and the like; the fructus xanthil has the effects of dispelling wind, eliminating dampness and the like; toad-grass, also known as Chinese forest frog grass, has the effects of detoxifying, relieving swelling, removing dampness, relieving itching and the like; the herba Swertiae Mileensis, herba Nepenthis has effects of clearing heat and relieving cough.
According to the disease symptoms of a patient, the components are added according to syndrome differentiation, and for the patient needing to soothe the liver and regulate vital energy, the radix bupleuri, the fructus aurantii and the fructus toosendan are added on the basis of the basic formula; poria, Atractylodis rhizoma, and radix Aconiti lateralis Preparata can be added on the basis of warming yang to promote diuresis.
The medicines of the invention have synergistic effect, and can achieve the effects of benefiting qi and nourishing blood, clearing and activating the channels and collaterals, promoting blood circulation by removing blood stasis, softening and resolving hard mass, clearing heat and detoxicating to improve myocardial microcirculation and improve myocardial ischemia and anoxia, thereby not only preventing myocardial hyperplasia and hypertrophy, but also reversing myocardial hypertrophy and effectively treating the myocardial hypertrophy; and according to different symptoms of patients with cardiac hypertrophy, medicaments are added according to differentiation of symptoms, so that the medicaments can be better administered according to symptoms, and the treatment effect is improved.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: an external application traditional Chinese medicine formula for treating cardiac hypertrophy comprises the following raw material medicines in parts by weight:
40 parts of astragalus membranaceus, 25 parts of peach kernels, 25 parts of safflower, 25 parts of salvia miltiorrhiza, 25 parts of lumbricus, 25 parts of cocklebur fruit, 25 parts of toad grass, 25 parts of pig leafy grass, 25 parts of radix bupleuri, 25 parts of fructus aurantii and 25 parts of fructus toosendan.
Example 2: an external application traditional Chinese medicine formula for treating cardiac hypertrophy comprises the following raw material medicines in parts by weight:
40 parts of astragalus membranaceus, 25 parts of peach kernels, 25 parts of safflower, 25 parts of salvia miltiorrhiza, 25 parts of lumbricus, 25 parts of cocklebur fruit, 25 parts of bufonid, 25 parts of pig leafy herb, 25 parts of poria cocos, 25 parts of bighead atractylodes rhizome and 25 parts of monkshood.
Example 3: an external application traditional Chinese medicine formula for treating cardiac hypertrophy comprises the following raw material medicines in parts by weight:
40 parts of astragalus, 25 parts of peach kernel, 25 parts of safflower, 25 parts of salvia miltiorrhiza, 25 parts of earthworm, 25 parts of cocklebur fruit, 25 parts of toad grass and 25 parts of pig leaf grass.
Implementation 4: an external application traditional Chinese medicine formula for treating cardiac hypertrophy comprises the following raw material medicines in parts by weight:
40 parts of astragalus membranaceus, 25 parts of peach kernels, 25 parts of safflower, 25 parts of salvia miltiorrhiza, 40 parts of lumbricus, 25 parts of cocklebur fruit, 25 parts of toad grass, 25 parts of pig leafy grass, 20 parts of radix bupleuri, 20 parts of fructus aurantii and 20 parts of fructus toosendan.
The treatment modalities of examples 1 to 4 were: weighing the raw materials according to the amount, adding water to prepare decoction, soaking the decoction into a decoction medicament with the temperature of 40-48 ℃ by using a plurality of layers of gauzes, taking out the plurality of layers of gauzes, screwing the gauzes until no liquid medicine drips, placing the gauze on an affected part of a heart for external application, controlling the medicament on the gauzes to be about 42 ℃ in the external application process, externally applying the gauze for about 2 hours once, preferably 2 times a day, and generally improving related symptoms after 2-3 days, such as chest distress, chest pain, suffocation, shortness of breath, dizziness and other symptoms, wherein the symptoms are completely eliminated after half a year to 1 year, and the cardiac hypertrophy is reversed.
Example 5: typical case
Case 1: zeng-one, woman 72 years old, it carries on the ultrasonic diagnosis to the heart in Shandong provincial Hospital, the ultrasonic diagnosis result is that its every segment cardiac muscle of left ventricle thickens commonly, it is remarkable that basal segment cardiac muscle and left ventricle apical cardiac muscle thicken, basal segment cardiac muscle is about 1.54cm thickest, it is protruding to the left ventricle outflow tract, cause its inner diameter to narrow, about 1.11cm, apical cardiac muscle thickest about 1.70cm, it is diagnosed as the left ventricle is fat, and it is accompanied by arrhythmia, palpitation, short breath and having symptoms such as the onset, etc., to its pulse diagnosis: the traditional Chinese medicine is used for treating pale tongue, thin and white fur and deep and thready and weak pulse, the symptoms are relieved after the traditional Chinese medicine is externally applied for 1 month, the ultrasonic retest is carried out after the treatment is continuously consolidated for 7 months, the ultrasonic result shows that the basal segment of the ventricular septum is about 1.23cm, the basal segment protrudes to the left ventricular outflow tract, the inner diameter of the basal segment is about 1.45cm, the thickness of the cardiac muscle of the apex of the left ventricle is about 1.05cm, the hypertrophy of the cardiac muscle of a patient is effectively treated, and the symptoms completely disappear and return to normal after the treatment is continuously consolidated for 1 year.
Case 2: xuan, male, 78 years old, it carries on the ultrasonic diagnosis in Shandong province's department of Chinese medicine, it is about 26384, from the ultrasonic diagnosis result its indoor space is about 1.2cm thick, the wall thickness is about 1.0cm behind the left room, accompanied by chest distress, chest pain, suffocated breath, symptoms such as dizziness, etc., it is a slight cardiac hypertrophy to diagnose it, combine Chinese medicine pulse diagnosis, treat it with the Chinese medicinal formulation of example 1, after treating for 1 month continuously externally, carry on the ultrasonic reexamination, basically resume to the normal value.
The present invention and the embodiments thereof have been described above, but the description is not limited thereto, and the embodiment shown is only one of the embodiments of the present invention, and the actual structure is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (4)

1. An external application traditional Chinese medicine prescription for treating cardiac hypertrophy is characterized by comprising the following raw material medicines: radix astragali, semen Persicae, Carthami flos, Saviae Miltiorrhizae radix, Lumbricus, fructus Xanthii, Bufo siccus, and herba Swertiae Dilutae.
2. The externally applied traditional Chinese medicine formula for treating myocardial hypertrophy as claimed in claim 1, wherein the formula comprises the following raw material medicines in parts by weight:
20-50 parts of astragalus membranaceus, 20-50 parts of peach kernels, 20-50 parts of safflower, 20-50 parts of salvia miltiorrhiza, 20-50 parts of lumbricus, 20-50 parts of cocklebur fruits, 20-50 parts of bufonid, 20-50 parts of pig-leaf weeds, 20-50 parts of radix bupleuri, 20-50 parts of fructus aurantii and 20-50 parts of fructus toosendan.
3. The externally applied traditional Chinese medicine formula for treating myocardial hypertrophy as claimed in claim 1, wherein the formula comprises the following raw material medicines in parts by weight:
20-50 parts of astragalus membranaceus, 20-50 parts of peach kernels, 20-50 parts of safflower, 20-50 parts of salvia miltiorrhiza, 20-50 parts of lumbricus, 20-50 parts of cocklebur fruits, 20-50 parts of bufonid, 20-50 parts of pig-leaf weeds, 20-50 parts of poria cocos, 20-50 parts of bighead atractylodes rhizome and 20-50 parts of monkshood.
4. A topical formulation of Chinese medicine according to any one of claims 1 to 3 for the treatment of myocardial hypertrophy, wherein the method of use is: weighing the raw materials according to the amount, adding water to prepare decoction, soaking the decoction into a plurality of layers of gauze, taking out the plurality of layers of gauze until no liquid medicine drips, placing the gauze on an affected part of a heart for external application, and controlling the medicine on the gauze to be about 42 ℃ in the external application process.
CN202111025365.6A 2021-09-02 2021-09-02 External application traditional Chinese medicine formula for treating cardiac hypertrophy Withdrawn CN113750146A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111025365.6A CN113750146A (en) 2021-09-02 2021-09-02 External application traditional Chinese medicine formula for treating cardiac hypertrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111025365.6A CN113750146A (en) 2021-09-02 2021-09-02 External application traditional Chinese medicine formula for treating cardiac hypertrophy

Publications (1)

Publication Number Publication Date
CN113750146A true CN113750146A (en) 2021-12-07

Family

ID=78792584

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111025365.6A Withdrawn CN113750146A (en) 2021-09-02 2021-09-02 External application traditional Chinese medicine formula for treating cardiac hypertrophy

Country Status (1)

Country Link
CN (1) CN113750146A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108837075A (en) * 2018-09-11 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 The Chinese medicine preparation and medicine-smoking production method for treating the early coronary disease of qi deficiency to blood stasis
CN109966461A (en) * 2019-04-11 2019-07-05 中国中医科学院广安门医院 A kind of Chinese medicine composition and its application for treating dilated cardiomyopathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108837075A (en) * 2018-09-11 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 The Chinese medicine preparation and medicine-smoking production method for treating the early coronary disease of qi deficiency to blood stasis
CN109966461A (en) * 2019-04-11 2019-07-05 中国中医科学院广安门医院 A kind of Chinese medicine composition and its application for treating dilated cardiomyopathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
余元勋等: "《中国分子心肌病学》", 30 July 2017, 安徽科学技术出版社 *
张欣: "丹参活血汤治疗冠心病心绞痛66例", 《陕西中医》 *
栾杰男等: "通脉地仙丸对促进缺血心肌血管新生作用的研究", 《长春中医药大学学报》 *

Similar Documents

Publication Publication Date Title
CN100382839C (en) Chinese-medicinal composition for treating coronary heart disease
CN101011522B (en) Chinese traditional medicine for treating cardiopathy
CN1240416C (en) Medicine for curing hypertension and its preparation method
CN101683417A (en) Traditional Chinese medicine composition with function of warming yang and gore removing
CN104547939A (en) Traditional Chinese medicine preparation for treating premature beat
CN104258350A (en) Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation
CN103041119A (en) Traditional Chinese medicine for treating cardiac disease
CN104398997B (en) It is a kind of for Chinese medicine composition of scleroderma circumscriptum and preparation method thereof
CN113750146A (en) External application traditional Chinese medicine formula for treating cardiac hypertrophy
CN104689132A (en) Traditional Chinese medicine composition for treating psoriasis
CN102861169B (en) Traditional Chinese medicine compound for treating paroxysmal supraventricular tachycardia
CN104524288A (en) Traditional Chinese medicinal composition for treating hypertension
CN102488774B (en) Chinese medicinal powder for treating canker sore and preparation method thereof
CN101716296A (en) Traditional Chinese medicine pill for treating psoriasis
CN1132603C (en) Compound Wuduqing capsule of blister beetle
CN101773590A (en) Chinese drug capsule for treatment of coronary heart disease with qi deficiency and blood stasis
CN111388623B (en) Traditional Chinese medicine for treating coronary heart disease
CN104887920A (en) Hypoglycemic navel patch and preparation method thereof
CN104784444A (en) Traditional Chinese medicine composition for treating hypertensive heart diseases and preparation method thereof
CN113694124A (en) Medical formula for treating bone diseases and pains
CN104587253A (en) Traditional Chinese medicine composition for preventing and treating radiodermatitis of head and neck and preparation method thereof
CN111437360A (en) Cancer-eliminating yang-strengthening plaster
CN102641374B (en) Traditional Chinese decoction for treating chronic bronchitis
CN110711241A (en) Body-strengthening body-resistance-strengthening blood stasis-removing paste and preparation method thereof
CN106620433A (en) Traditional Chinese medicine composition for treating leuconychia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20211207